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Fabry Disease With Resting Outflow Obstruction
Masquerading as Hypertrophic Cardiomyopathy
Jeffrey B. Geske, MD,* Hayan Jouni, MD,* Marie C. Aubry, MD,y Bernard J. Gersh, MB, CHB, DPHIL*
Rochester, Minnesota67-year-old man with prior coronary artery bypass grafting, rheumatic fever with mitralAvalve repair, and unexplained stage IV chronic kidney disease was referred for evaluationof obstructive hypertrophic cardiomyopathy because of progressive exertional dyspnea.
Physical examination showed angiokeratomas (A). Electrocardiography showed sinus bradycardia,
right bundle branch block, left anterior fascicular block, and high voltages with anterolateral
T-wave changes (B). Transthoracic echocardiography revealed an ejection fraction of 59%, right
and concentric left ventricular hypertrophy, and a resting left ventricular outﬂow gradient of
55 mm Hg (C to E, Online Videos 1 and 2). The patient’s rash, striking electrocardiogram,
right ventricle involvement, and renal failure raised suspicion of an alternate diagnosis despite
resting obstruction. The patient’s serum alpha-galactosidase level was 0.0 nmol/h/mg (normal
>23.1 nmol/h/mg), and examination of a right ventricular biopsy specimen revealed myocyte
hypertrophy with cytoplasmic vacuolization (F), conﬁrming Fabry disease. Differentiating Fabry
disease from hypertrophic cardiomyopathy is crucial given the therapeutic and prognostic
differences. The patient is currently undergoing evaluation for enzyme replacement therapy.
